Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) - Global Forecast to 2028

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) - Global Forecast to 2028

The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. The rising focus on decentralized diagnostics and the growing demand for CLIA-waived PoC tests have driven the use of PoC technologies. The trend towards decentralized PoC testing in the infectious disease diagnostics market is further fueled by the need for more efficient healthcare delivery. Centralized laboratories often face challenges such as longer turnaround times and logistical complexities, particularly in remote or underserved areas. The decentralization of testing to point-of-care settings empowers healthcare professionals with the ability to conduct diagnostics at the patient's side, reducing the time between sample collection and result delivery. This paradigm shift not only supports timely patient care but also aids in the prompt identification and containment of infectious diseases, ultimately contributing to improved public health outcomes.

“PoC testing segment accounted for the highest growth rate in the infectious disease diagnostics market, by type of testing, during the forecast period.”

The infectious disease diagnostics market is bifurcated into laboratory testing and PoC testing. The PoC testing segment in the infectious disease diagnostics market is experiencing substantial growth. The growth of the PoC segment is being fueled by the investments made by numerous companies, including their focus on new developments such as product launches and acquisitions. One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as a faster diagnosis rate are the major factors driving the demand for PoC tests.

“DNA sequencing & next-generation sequencing segment accounted for the highest growth rate in the infectious disease diagnostics market, by technology, during the forecast period.”

The infectious disease diagnostics market is bifurcated into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies based on technology. DNA sequencing & next-generation sequencing segment is expected to account for the highest CAGR during the forecast period. DNA sequencing is an easy platform that can be set up directly in the clinic for quick results. The ability to sequence DNA has opened opportunities for applications in various research fields, such as personalized medicine, cancer research, drug discovery, and agricultural and animal sciences. Factors such as advancements in sequencing technologies, a wide range of applications of sequencing technologies, and the growing demand for personalized medicine are factors expected to support market growth in the coming years.

“Asia Pacific: The fastest-growing region infectious disease diagnostics market”

The global infectious disease diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of infectious diseases, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for infectious disease diagnostics companies in this region.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, dna sequencing & next-generation sequencing, dna microarray, and other technologies), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the infectious disease diagnostics market. Competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.

Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.